<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36243024</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>400</Volume><Issue>10362</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>29</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance.</ArticleTitle><Pagination><StartPage>1531</StartPage><EndPage>1538</EndPage><MedlinePgn>1531-1538</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(22)01804-9</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(22)01804-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">The international spread of poliovirus exposes all countries to the risk of outbreaks and is designated a Public Health Emergency of International Concern by WHO. This risk can be exacerbated in countries using inactivated polio vaccine, which offers excellent protection against paralysis but is less effective than oral vaccine against poliovirus shedding, potentially allowing circulation without detection of paralytic cases for long periods of time. Our study investigated the molecular properties of type 2 poliovirus isolates found in sewage with an aim to detect virus transmission in the community.</AbstractText><AbstractText Label="METHODS">We performed environmental surveillance in London, UK, testing sewage samples using WHO recommended methods that include concentration, virus isolation in cell culture, and molecular characterisation. We additionally implemented direct molecular detection and determined whole-genome sequences of every isolate using novel nanopore protocols.</AbstractText><AbstractText Label="FINDINGS">118 genetically linked poliovirus isolates related to the serotype 2 Sabin vaccine strain were detected in 21 of 52 sequential sewage samples collected in London between Feb 8 and July 4, 2022. Expansion of environmental surveillance sites in London helped localise transmission to several boroughs in north and east London. All isolates have lost two key attenuating mutations, are recombinants with a species C enterovirus, and an increasing proportion (20 of 118) meet the criterion for a vaccine-derived poliovirus, having six to ten nucleotide changes in the gene coding for VP1 capsid protein.</AbstractText><AbstractText Label="INTERPRETATION">Environmental surveillance allowed early detection of poliovirus importation and circulation in London, permitting a rapid public health response, including enhanced surveillance and an inactivated polio vaccine campaign among children aged 1-9 years. Whole-genome sequences generated through nanopore sequencing established linkage of isolates and confirmed transmission of a unique recombinant poliovirus lineage that has now been detected in Israel and the USA.</AbstractText><AbstractText Label="FUNDING">Medicines and Healthcare products Regulatory Agency, UK Health Security Agency, Bill &amp; Melinda Gates Foundation, and National Institute for Health Research Medical Research Council.</AbstractText><CopyrightInformation>&#xa9; 2022 Crown Copyright claimed by UK, Canadian or Australian Government employee. This is an Open Access article under the OGL 3.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klapsa</LastName><ForeName>Dimitra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Vaccines, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Potters Bar, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilton</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Vaccines, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Potters Bar, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zealand</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Environmental Monitoring for Health Protection, Data, Analytics and Surveillance Group, UK Health Security Agency, Nobel House, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bujaki</LastName><ForeName>Erika</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Vaccines, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Potters Bar, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saxentoff</LastName><ForeName>Eugene</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>World Health Organization Regional Office for Europe, Regional Polio Laboratory Network, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troman</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Alexander G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tedcastle</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Vaccines, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Potters Bar, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majumdar</LastName><ForeName>Manasi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Vaccines, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Potters Bar, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mate</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Analytical and Biological Science, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Potters Bar, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akello</LastName><ForeName>Joyce O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huseynov</LastName><ForeName>Shahin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>World Health Organization Regional Office for Europe, Regional Polio Laboratory Network, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeb</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Environmental Monitoring for Health Protection, Data, Analytics and Surveillance Group, UK Health Security Agency, Nobel House, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zambon</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Polio Laboratory, Reference Services Division, UK Health Security Agency, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>North East and North Central London Health Protection Team, UK Health Security Agency, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagan</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>World Health Organization Regional Office for Europe, Regional Polio Laboratory Network, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wade</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Environmental Monitoring for Health Protection, Data, Analytics and Surveillance Group, UK Health Security Agency, Nobel House, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramsay</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Immunisation and Vaccine Preventable Disease Division, UK Health Security Agency, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassly</LastName><ForeName>Nicholas C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saliba</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Immunisation and Vaccine Preventable Disease Division, UK Health Security Agency, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Vaccines, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Potters Bar, UK. Electronic address: javier.martin@nibsc.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant><Grant><GrantID>INV-024477</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/R015600/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012722">Sewage</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2022 Oct 29;400(10362):1491-1492. doi: 10.1016/S0140-6736(22)01885-2</RefSource><PMID Version="1">36243023</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012722" MajorTopicYN="N">Sewage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008131" MajorTopicYN="N" Type="Geographic">London</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004784" MajorTopicYN="N">Environmental Monitoring</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests We declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>15</Day><Hour>19</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36243024</ArticleId><ArticleId IdType="pmc">PMC9627700</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(22)01804-9</ArticleId><ArticleId IdType="pii">S0140-6736(22)01804-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>UK Health Security Agency  Polio: the green book, chapter 26 v2.0.2013. https://www.gov.uk/government/publications/polio-the-green-book-chapter-26</Citation></Reference><Reference><Citation>WHO Certification of poliomyelitis eradication - European region. Morb Mortal Wkly Rep. 2002;51:572&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">12139184</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Polio Case Count. 2022. https://extranet.who.int/polis/public/CaseCount.aspx</Citation></Reference><Reference><Citation>Alleman MM, Jorba J, Henderson E, et al. Update on vaccine-derived poliovirus outbreaks - worldwide, January 2020-June 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1691&#x2013;1699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8659190</ArticleId><ArticleId IdType="pubmed">34882653</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Statement of the thirty-second Polio IHR Emergency Committee. 2022. https://www.who.int/news/item/24-06-2022-statement-of-the-thirty-second-polio-ihr-emergency-committee</Citation></Reference><Reference><Citation>Asghar H, Diop OM, Weldegebriel G, et al. Environmental surveillance for polioviruses in the Global Polio Eradication Initiative. J Infect Dis. 2014;210(suppl 1):S294&#x2013;S303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10578309</ArticleId><ArticleId IdType="pubmed">25316848</ArticleId></ArticleIdList></Reference><Reference><Citation>Lickness JS, Gardner T, Diop OM, et al. Surveillance to track progress toward polio eradication &#x2013; worldwide, 2018&#x2013;2019. MMWR Morb Mortal Wkly Rep. 2020;69:623&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">32437342</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra S, Mindermann S, Sharma M, et al. Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England. EClinicalMedicine. 2021;39</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8349999</ArticleId><ArticleId IdType="pubmed">34401689</ArticleId></ArticleIdList></Reference><Reference><Citation>Hovi T, Blomqvist S, Nasr E, et al. Environmental surveillance of wild poliovirus circulation in Egypt&#x2014;balancing between detection sensitivity and workload. J Virol Methods. 2005;126:127&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">15847928</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndiaye AK, Diop PA, Diop OM. Environmental surveillance of poliovirus and non-polio enterovirus in urban sewage in Dakar, Senegal (2007&#x2013;2013) Pan Afr Med J. 2014;19:243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4377292</ArticleId><ArticleId IdType="pubmed">25848458</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson Muluh T, Hamisu AW, Craig K, et al. Contribution of environmental surveillance toward interruption of poliovirus transmission in Nigeria, 2012&#x2013;2015. J Infect Dis. 2016;213(suppl 3):131&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818559</ArticleId><ArticleId IdType="pubmed">26908747</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande JM, Shetty SJ, Siddiqui ZA. Environmental surveillance system to track wild poliovirus transmission. Appl Environ Microbiol. 2003;69:2919&#x2013;2927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC154486</ArticleId><ArticleId IdType="pubmed">12732567</ArticleId></ArticleIdList></Reference><Reference><Citation>Mas Lago P, Caceres VM, Galindo MA, et al. Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: implications for stopping polio vaccination after global eradication. Int J Epidemiol. 2001;30:1029&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pubmed">11689516</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T, Hamasaki M, Yoshitomi H, et al. Environmental surveillance of poliovirus in sewage water around the introduction period for inactivated polio vaccine in Japan. Appl Environ Microbiol. 2015;81:1859&#x2013;1864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4325164</ArticleId><ArticleId IdType="pubmed">25556189</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang QS, Greening G, Baker MG, et al. Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand. Lancet. 2005;366:394&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054940</ArticleId></ArticleIdList></Reference><Reference><Citation>Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PloS Pathog. 2012;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3330118</ArticleId><ArticleId IdType="pubmed">22532797</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin GR, Grassly NC, Sutter RW, et al. Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis. Lancet Infect Dis. 2019;19:1121&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">31350192</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman LM, Gavrilin E, Jorba J, et al. Molecular epidemiology of silent introduction and sustained transmission of wild poliovirus type 1, Israel, 2013. Euro Surveill. 2014;19</Citation><ArticleIdList><ArticleId IdType="pubmed">24576471</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorba J, Campagnoli R, De L, Kew O. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J Virol. 2008;82:4429&#x2013;4440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2293050</ArticleId><ArticleId IdType="pubmed">18287242</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health and Security Agency  Polio: national guidelines. Guidance for the surveillance, investigation and management of suspected polio cases in the UK. 2019. https://www.gov.uk/government/publications/polio-national-guidelines</Citation></Reference><Reference><Citation>Majumdar M, Klapsa D, Wilton T, et al. Isolation of vaccine-like poliovirus strains in sewage samples from the United Kingdom. J Infect Dis. 2018;217:1222&#x2013;1230.</Citation><ArticleIdList><ArticleId IdType="pubmed">29309594</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurbriggen S, Tobler K, Abril C, et al. Isolation of sabin-like polioviruses from wastewater in a country using inactivated polio vaccine. Appl Environ Microbiol. 2008;74:5608&#x2013;5614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2547022</ArticleId><ArticleId IdType="pubmed">18641161</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumdar M, Sharif S, Klapsa D, et al. Environmental surveillance reveals complex enterovirus circulation patterns in human populations. Open Forum Infect Dis. 2018;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6201154</ArticleId><ArticleId IdType="pubmed">30377626</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw AG, Majumdar M, Troman C, et al. Rapid and sensitive direct detection and identification of poliovirus from stool and environmental surveillance samples by use of nanopore sequencing. J Clin Microbiol. 2020;58</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7448630</ArticleId><ArticleId IdType="pubmed">32611795</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Polio laboratory manual, 4th edn. 2004. https://apps.who.int/iris/handle/10665/68762 2021</Citation></Reference><Reference><Citation>Stern A, Yeh MT, Zinger T, et al. The evolutionary pathway to virulence of an RNA virus. Cell. 2017;169:35&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5787669</ArticleId><ArticleId IdType="pubmed">28340348</ArticleId></ArticleIdList></Reference><Reference><Citation>Polio Global Eradication Initiative  Israel. Status: affected by circulating vaccine-derived poliovirus type 3 (cVDPV3) 2022. https://polioeradication.org/news-post/circulating-vaccine-derived-poliovirus-type-3-confirmed-in-israel/</Citation></Reference><Reference><Citation>Polio Global Eradication Initiative  Updated statement on report of polio detection in United States. 2022. https://polioeradication.org/news-post/report-of-polio-detection-in-united-states/</Citation></Reference><Reference><Citation>Link-Gelles R, Schnabel Ruppert P, Bryon Backenson P, et al. Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewater &#x2014; New York, June&#x2013;August 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1065&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9400530</ArticleId><ArticleId IdType="pubmed">35980868</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaliner E, Kopel E, Anis E, et al. The Israeli public health response to wild poliovirus importation. Lancet Infect Dis. 2015;15:1236&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">26213249</ArticleId></ArticleIdList></Reference><Reference><Citation>Joint Committee on Vaccination and Immunisation  Joint Committee on Vaccination and Immunisation statement on vaccination strategy for the ongoing polio incident. 2022. https://www.gov.uk/government/publications/vaccination-strategy-for-ongoing-polio-incident-jcvi-statement/joint-committee-on-vaccination-and-immunisation-statement-on-vaccination-strategy-for-the-ongoing-polio-incident</Citation></Reference><Reference><Citation>UK Health Security Agency  Cover of vaccination evaluated rapidly (COVER) programme 2021 to 2022: quarterly data. 2022. https://www.gov.uk/government/statistics/cover-of-vaccination-evaluated-rapidly-cover-programme-2021-to-2022-quarterly-data</Citation></Reference><Reference><Citation>UK Health Security Agency  Inactivated polio vaccine (IPV) booster campaign: information for healthcare practitioners. 2022. https://www.gov.uk/government/publications/inactivated-polio-vaccine-ipv-booster-information-for-healthcare-practitioners/inactivated-polio-vaccine-ipv-booster-campaign-information-for-healthcare-practitioners</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>